Trial reportHypertension (Dallas, Tex. : 1979)2024
Impact of Antihypertensive Medication Changes After Renal Denervation Among Different Patient Groups: SPYRAL HTN-ON MED.
Trial report in Hypertension (Dallas, Tex. : 1979), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02439775 (Global Clinical Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System in Patients With Uncontrolled Hypertension on Standard Medical Therapy), which is not on this map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Global Clinical Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System in Patients With Uncontrolled Hypertension on Standard Medical Therapy (SPYRAL HTN-ON MED)
Who cites it
23 citing papers in PubMed, 29 citations in OpenAlex.
- Three-Year Durability of Radiofrequency Renal Denervation: SPYRAL HTN-ON MED.Journal of the American Heart Association · 2026Trial
- Fluctuations in adherence to antihypertensive medication and cardiovascular outcomes: a secondary analysis of the SPRINT trial.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Trial
- Kidney Denervation: Latest Breakthroughs and Insights.Clinical journal of the American Society of Nephrology : CJASN · 2026Review
- Application of metabolomics in hypertension research: A bibliometric study and literature review.International journal of cardiology. Heart & vasculature · 2026Review
- Addressing Hypertension Treatment Disparities Via Renal Denervation.Current hypertension reports · 2026Review
- Patient Selection and Renal Denervation.Current hypertension reports · 2026Review
- Ten-Year Results of Therapeutic Intravascular Ultrasound Renal Denervation in Resistant Hypertension: A Prospective Single-Center Study.Kidney & blood pressure research · 2026Article
- Resistant Blood Pressure: New Frontiers in Interventional Hypertension Therapy.Cardiology and therapy · 2025Review
- Renal denervation for hypertension.Nature reviews. Cardiology · 2025Review
- Hypertension: a lymphatic disease?Clinical science (London, England : 1979) · 2025Review
- In these cases, I treat hypertension with renal ablation.European heart journal supplements : journal of the European Society of Cardiology · 2025Article
- Renal nerves in physiology, pathophysiology and interoception.Nature reviews. Nephrology · 2025Review
- Cost-effectiveness of catheter-based radiofrequency renal denervation for the treatment of uncontrolled hypertension: an analysis for the UK based on recent clinical evidence.European heart journal. Quality of care & clinical outcomes · 2024Article
- Medication Changes After Renal Denervation: Current Evidence and Patient Perspectives.Journal of the American Heart Association · 2024Review
- Tackling the Disproportionate Burden of Resistant Hypertension in US Black Adults.Current cardiology reports · 2024Review
- Consensus statement on renal denervation by the Joint Committee of Japanese Society of Hypertension (JSH), Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT), and the Japanese Circulation Society (JCS).Cardiovascular intervention and therapeutics · 2024Article
- Catheter-Based Radiofrequency Renal Denervation in the United States: A Cost-Effectiveness Analysis Based on Contemporary Evidence.Journal of the Society for Cardiovascular Angiography & Interventions · 2024Article
- What are the ideal metrics for assessing the quality of long-term stabilized "perfect" 24-h BP control after renal denervation?Hypertension research : official journal of the Japanese Society of Hypertension · 2024Review
- Renal denervation up-to-date 2024: evidence and perspectives in Japan.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Catheter-Based Renal Denervation Ready for the Management of Hypertension: Evidence, Challenges, and Perspectives.Journal of the American Heart Association · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 15 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe SPYRAL HTN-ON MED (Global Clinical Study of Renal Denervation With the Symplicity Spyral Multi-electrode Renal Denervation System in Patients With Uncontrolled Hypertension in the Absence of Antihypertensive Medications)trial showed significant office and nighttime systolic blood pressure (BP) reductions in patients with hypertension following renal denervation (RDN) compared with sham-control patients, despite similar 24-hour BP reductions. We compared antihypertensive medication and BP changes among prespecified subpopulations.
methodsThe multicenter, randomized, sham-controlled, blinded SPYRAL HTN-ON MED trial (n=337) evaluated BP changes after RDN compared with a sham procedure in patients with hypertension prescribed 1 to 3 antihypertensive drugs. Most patients (n=187; 54%) were enrolled outside the United States, while 156 (46%) US patients were enrolled, including 60 (18%) Black Americans.
resultsChanges in detected antihypertensive drugs were similar between RDN and sham group patients in the outside US cohort, while drug increases were significantly more common in the US sham group compared with the RDN group. Patients from outside the United States showed significant reductions in office and 24-hour mean systolic BP at 6 months compared with the sham group, whereas BP changes were similar between RDN and sham in the US cohort. Within the US patient cohort, Black Americans in the sham control group had significant increases in medication burden from baseline through 6 months (
conclusionsPatients enrolled outside the United States had minimal antihypertensive medication changes between treatment groups and had significant office and 24-hour BP reductions compared with the sham group. Increased antihypertensive drug burden in the US sham cohort, especially among Black Americans, may have diluted the treatment effect in the combined trial population. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02439775.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.